Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Fall;14(3):e62-7.

The art of healing broken hearts in breast cancer patients: Trastuzumab and heart failure

Jonathan R Walker  1 , Pawan K Singal, Davinder S Jassal
Affiliations

The art of healing broken hearts in breast cancer patients: Trastuzumab and heart failure

Jonathan R Walker et al. Exp Clin Cardiol. 2009 Fall.

Abstract

Breast cancer, a leading cause of increased morbidity and mortality among women, overexpresses the human epidermal growth factor receptor 2 in approximately 20% to 30% of cases. Trastuzumab (Trz), a monoclonal antibody against the human epidermal growth factor receptor 2, improves survival in breast cancer patients in both the adjuvant and metastatic settings. Despite the therapeutic benefits of Trz, there is an increased incidence of cardiotoxicity, particularly when administered following anthracycline-based chemotherapy. The pathogenesis underlying Trz-mediated cardiotoxicity remains poorly understood. The present review focuses on the current understanding of Trz-mediated cardiotoxicity from both the basic and clinical science perspectives.

Keywords: Cardiac MRI; Cardiomyopathy; Echocardiography; Renin-angiotensin system; Trastuzumab.

PubMed Disclaimer

Figures

Figure 1)
Figure 1)
Normal heterodimerization of the human epidermal growth factor receptor 2 (HER2) with adjacent receptors (ErbB1, ErbB3, ErbB4, gp1130 and IL-6). Trastuzumab binds to HER2, inhibiting downstream signalling with subsequent development of a dilated cardiomyopathy
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94:153–6. - PubMed
    1. Baselga J. A new anti-ErbB2 strategy in the treatment of cancer: Prevention of ligand-dependent ErbB2 receptor heterodimerization. Cancer Cell. 2002;2:93–5. - PubMed
    1. Marrett LD, De P, Airia P, Dryer D, Steering Committee of Canadian Cancer Statistics 2008 Cancer in Canada in 2008. CMAJ. 2008;179:1163–70. - PMC - PubMed
    1. Pasche B. Recent advances in breast cancer genetics. In: Gradishar WJ, Wood WC, editors. Advances in Breast Cancer Management. Second Edition. New York: Springer; 2008. pp. 1–10. - PMC - PubMed
    1. Lalloo F, Varley J, Ellis D, et al. Early Onset Breast Cancer Study Group Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. Lancet. 2003;361:1101–2. - PubMed